Friday 6 September 15:30 - 16:30

In this symposium hosted by Mölnlycke Health Care, experts will introduce a clinical decision support tool. This tool is designed to optimise the use of Granulox® topical hemoglobin spray for managing diabetes-related foot ulcers. Additionally, the experts will explore the mechanism of action of Granulox®, with a focus on its ability to deliver oxygen to hypoxic wounds.

Moderators:
- Matthew Malone, PhD, FFPM, RCPS (Glasg)
- Prof Dr. José Luis Lázaro-Martínez
- Susanna Roe, Ph.D

Saturday 7 September 13:30 - 14:00

Sicco Bus:
“Foot disease is a major problem in patients with diabetes mellitus. Every 20 seconds someone in the world loses a leg because of diabetes. A foot ulcer precedes most amputations.Changes in foot biomechanics during ambulation are an important risk factor for foot ulceration. In particular, increases in plantar pressures have been indicated as contributing factor. Therefore, reduction of these pressures, called offloading, is important in the treatment of these chronic wounds.Offloading a foot ulcer can be achieved by many different modalities and devices, that all aim to redistribute the pressure under the foot in order to offloading the ulcer region. The mechanisms by which this can be achieved will be discussed, to help better understand foot biomechanics, together with the association between offloading efficacy and healing efficacy.The recommendations from the most recent IWGDF guidelines on offloading will be presented”

Professor. JOSÉ LUIS LÁZARO MARTÍNEZ:
”Diabetic foot offloading is one of the cornerstones in the management of these patients. The IWGDF recommends selecting an offloading device based on the location of the ulcer, vascular status, and the presence of infection. However, there are other parameters that influence the selection of the offloading device, such as patient activity, body mass index, treatment acceptance, and impact on quality of life, among others. Selecting an effective, attractive, and easy-to-use device is key to improving patient outcomes. In this symposium, we will analyze the keys to selecting an offloading device and why they are important for achieving the best clinical and quality of life outcomes.”

Presenters:
- Prof. Sicco Bus
- Prof. José Luis Lázaro-Martínez

Moderators:
- Prof. Luigi Uccioli and Prof. Venu Kavarthapu

Saturday 7 September 14:05 - 14:20

S53P4 bioactive glass produced by Bonalive®, is a specific type of bone graft substitute used in various medical applications, including the treatment of diabetic foot syndrome. Its unique composition, which combines bioactive, osteoconductive, osteostimulatory, bactericidal, and bacteriostatic properties, makes it suitable for treating the most complicated diabetic foot cases, even those with osteomyelitis. These properties make this product promising for long-term clinical use, particularly in patients with chronic hard-toheal bone infections. The actual podiatric management and Bonalive S53P4 usage is typically performed as follows: the first step is the careful selection of suitable patients for this bone substitute method. The surgical approach, technique, and application of the bioactive glass have specific requirements that influence the healing outcome. The success of the entire treatment also heavily relies on postoperative podiatric care, especially offloading therapy and diligent patient monitoring. During this satellite symposium, we will present our pioneering clinical results and experiences with S53P4 treatment in our patient cohort. Through detailed case reports, we will showcase the journeys of patients from their initial referral to the podiatric clinic to the completion of the treatment process. This overview, including extensive wound photo documentation, radiological documentation, and microbiological findings, aims to serve as inspiration, guidance, or a “recipe book” for utilizing the benefits of bioactive glass in daily podiatric and surgical practice. The main lecture on this topic is under abstract ID: OP32 (Sutoris et al.: Experimental Bone Tissue Substitution in Diabetic Osteomyelitis).

Presenters:
- Karol Sutoris, MD, PhD, Head of Podiatric Surgery Division, Transplantation Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- Vladimíra Fejfarová, MD, PhD, Chairman of Podiatric section of Czech diabetes Association, Vice-chairman of Czech Wound and Management Association, Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

- Vladimira Fejfarova

Saturday 7 September 15:55 - 16:10

The financial and global burden of foot ulceration remains high, hence the pressing need to reduce healing time, and close the wound as soon as possible to avoid complications, such as infection and amputation.

The evidence from clinical trials and cost analysis studies suggests that using TLC-NOSF as a first line treatment and having it as an integral part of the standard of care for patients with different types of chronic wounds consistently results in significantly higher healing rates, shorter healing times, and positive cost savings than standard dressings used under similar conditions.

Real-life evidence has also confirmed the results documented in clinical trials and economic models across the world, including UK, France, Germany, China, Canada, Czech Republic, Australia and Spain, have all demonstrated it to be cost effectiveness and a dominant strategy to adopt, regardless of the healthcare settings involved or the characteristics of the patients and wounds treated.

Furthermore, the use of TLC-NOSF have been shown to improve the patients’ quality of life and also very well tolerated. Thus, all the available evidence supports the need for adopting this treatment approach, to reduce healing time, close the wound as soon as possible, and remains in alignment with national and international recommendations if we are to be successful in reducing the global burden of this disease.

Presenters:
- Dr Chris Manu (MD, FRCP)

Saturday 7 September 16:15 - 16.30

Dr Prash Vas and Maureen Bates be presenting on their experience using calcium sulfate (STIMULAN®). Their presentation will be how STIMULAN® is used as an antibiotic carrier – specifically designed to support the proactive management of dead space and surgical site infection, and illustrate the results from patient cases, highlighting the outcomes and benefits of using STIMULAN® in clinical practice on complex wounds.

Presenters:
- Dr Prash Vas
- Maureen Bates

Sunday 8 September 12:10 - 12:25

Prof Alberto PIAGGESI will introduce a novel, naturally-occurring extracellular matrix solution (MicroMatrix®) in the treatment of chronic diabetic wounds and present clinical case studies, discussing with the audience its indications in the management of this complex pathology.

Presenter:
- Prof. Alberto Piaggesi